Kidney cancer: now available in a new flavor.
The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL(-/-) kidney cancers is profoundly influenced by whether they produce both HIF2alpha and HIF1alpha or HIF2alpha alone.
Kaelin
William G
WG
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. william_kaelin@dfci.harvard.edu
D000818:Animals; D002277:Carcinoma / Q000378:metabolism; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis*; D008954:Models, Biological; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000378:metabolism
D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human